INSM Stock Price Today (October 2026) — Insmed Incorporated Analysis & Key Metrics 2026-10-07
Insmed Incorporated (INSM) is trading at $101.74, down 3.32% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $197.74 (94.4% upside).
- Volatility is moderate (37.68% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (296.10% YoY) alongside competitive pressures in the Biotechnology space.
INSM Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Insmed Incorporated - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $21.80B
P/E Ratio
Forward P/E: 151.85
Revenue Growth
Year over Year
Analyst Target
+94.4% upside potential
Key Investor Questions About INSM
What investors need to know before buying
Based on current market data, INSM presents a oversold technical setup with looking solid fundamentals.
- Technicals say: Oversold (RSI 25.48)
- Fundamentals say: Looking solid (debt and growth supportive)
INSM's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for INSM investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $739.72M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, INSM stock traded between $90.39 and $212.75 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 37.68% annualized volatility and β=0.62, the stock exhibits low sensitivity to market moves—making INSM suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
Did FDA Priority Review of ARIKAYCE ENCORE Data Just Shift Insmed's (INSM) Investment Narrative?
Insmed has reported that the U.S. FDA previously accepted its supplemental New Drug Application for ARIKAYCE for MAC lung disease under Priority Review, with a target action date of January 28, 2027, based on positive Phase 3b ENCORE data fulfilling a key post-marketing requirement. The ENCORE trial results could allow ARIKAYCE to be used earlier in the MAC disease course and support label expansion discussions in Japan, potentially broadening its treatment reach while maintaining a safety...
The Fund Exited Insmed (INSM) After the Investment Thesis Played Out
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.
Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio?
Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake
American Century Investments, an investment management company, released its second-quarter 2026 investor letter for the “American Century Investments Focused Dynamic Growth Fund”. The letter can be downloaded here. U.S. stocks advanced sharply with double-digit quarterly gains largely due to robust earnings, resilient economic data, and momentum in AI-related stocks. However, there was a slight pullback […]
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges?
Artisan Partners, an investment management company, released its second-quarter 2026 investor commentary for the “Artisan Global Opportunities Strategy”. The letter can be downloaded here. Global equities rebounded sharply during the quarter, with the MSCI ACWI Index returning 15.3% as resilient economic growth, strong corporate earnings, and continued enthusiasm around artificial intelligence supported markets despite persistent […]
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business
On August 6, Insmed (NASDAQ:INSM) reported second-quarter results that mark a turning point for a company long defined by red ink. Total revenue hit $425.5 million, up 296% from the same quarter of 2025, and the net loss shrank from $321.7 million a year ago to just $13.2 million. The numbers tell the story of […]
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
Explore More Analysis for INSM
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 28, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Insmed Incorporated
Insmed Incorporated (INSM) is currently trading at $101.74. The RSI (14-day) is at 25.5, indicating oversold territory (potentially undervalued). Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $197.74 implies 94.4% upside from current levels. Volatility is moderate at 37.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Insmed Incorporated (INSM): The trailing P/E ratio is not available (the company may not be profitable). The forward P/E is 151.85. Price-to-Book is 36.11. Price-to-Sales is 24.05. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 23 analysts covering INSM, the consensus price target is $197.74. This represents a 94.4% upside from the current price of $101.74. The range spans from a low target of $169.00 to a high target of $243.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Insmed Incorporated (INSM) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Insmed Incorporated (INSM) investors include: 1. Moderate volatility (37.7% annualized)—price swings are notable. 2. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Insmed Incorporated's (INSM) current debt and financial health profile: Total debt stands at $739.72M. The debt-to-equity ratio is 0.98x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 3.72, indicating strong short-term liquidity. The quick ratio is 3.14. The company holds $1.16B in cash and equivalents. Free cash flow is negative at -$571.82M, which could limit the company's ability to manage debt obligations.